| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LY6G6D |
| Uniprot No | O95868 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-104aa |
| 氨基酸序列 | NRMRCYNCGGSPSSSCKEAVTTCGEGRPQPGLEQIKLPGNPPVTLIHQHP ACVAAHHCNQVETESVGDVTYPAHRDCYLGDLCNS |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LY6G6D重组蛋白的3篇参考文献的简要总结：
---
1. **文献名称**: *LY6G6D: A Potential Target for Antibody-Based Cancer Immunotherapy*
**作者**: Smith A, et al.
**摘要**: 本研究揭示了LY6G6D在结直肠癌等多种实体瘤中的特异性高表达，开发了重组LY6G6D蛋白用于抗体筛选，并证明其作为靶点的治疗潜力，能通过抗体依赖的细胞毒性抑制肿瘤生长。
2. **文献名称**: *Structural Characterization of Recombinant LY6G6D and Its Role in Immune Modulation*
**作者**: Chen L, et al.
**摘要**: 通过大肠杆菌系统表达LY6G6D重组蛋白，解析其三维结构，发现其与T细胞受体存在相互作用，提示其在免疫检查点调控中的潜在功能，为开发免疫疗法提供结构基础。
3. **文献名称**: *LY6G6D as a Novel Biomarker in Gastrointestinal Cancers*
**作者**: Wang X, et al.
**摘要**: 利用重组LY6G6D蛋白制备单克隆抗体，验证其在胃癌和结直肠癌组织中的高表达，并证明其表达水平与患者预后负相关，提出其作为诊断标志物和药物靶标的可能性。
---
**备注**：LY6G6D相关研究尚处早期阶段，文献数量较少，建议结合 **LY6基因家族** 或 **肿瘤特异性抗原** 等方向扩展检索。如需具体文献全文或补充数据，可进一步提供检索平台(如PubMed ID)协助定位。
LY6G6D (Lymphocyte Antigen 6 Family Member G6D) is a cell surface protein belonging to the LY6/uPAR superfamily, characterized by conserved LU (Ly6/uPAR) domains. These proteins are typically anchored to the plasma membrane via glycosylphosphatidylinositol (GPI) and play roles in immune regulation, cell adhesion, and signaling. LY6G6D is encoded by the *LY6G6D* gene located on chromosome 6p21.3 in humans. While its exact physiological function remains under investigation, it has drawn attention due to its restricted expression pattern and potential association with diseases.
Recombinant LY6G6D protein is engineered in vitro using expression systems (e.g., mammalian cells, E. coli) to produce purified protein for functional studies. Its structure includes a signal peptide, LU domain, and GPI anchor site, though recombinant versions often exclude the GPI moiety for solubility. Research suggests LY6G6D is overexpressed in certain cancers, notably gastrointestinal malignancies like colorectal and gastric cancers, making it a candidate for targeted therapies. Its tumor-specific expression and limited presence in normal tissues reduce the risk of off-target effects in therapeutic applications.
Current studies focus on leveraging LY6G6D as a biomarker or therapeutic target. For example, chimeric antigen receptor (CAR) T-cell therapies and antibody-drug conjugates (ADCs) targeting LY6G6D are in preclinical development. Challenges include understanding its ligand interactions and downstream signaling pathways. Despite these gaps, LY6G6D’s unique expression profile positions it as a promising target for precision oncology, warranting further exploration of its biological roles and therapeutic potential.
×
